<li>benazepril<p>valsartan, benazepril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li><li>captopril<p>valsartan, captopril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li><li>eluxadoline<p>valsartan increases levels of eluxadoline by decreasing metabolism. Avoid or Use Alternate Drug. Decrease eluxadoline dose to 75 mg PO BID if coadministered with OATP1B1 inhibitors. .</p></li><li>enalapril<p>valsartan, enalapril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li><li>fosinopril<p>valsartan, fosinopril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li><li>lisinopril<p>valsartan, lisinopril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li><li>lithium<p>valsartan increases toxicity of lithium by decreasing renal clearance. Avoid or Use Alternate Drug.</p></li><li>moexipril<p>valsartan, moexipril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li><li>perindopril<p>valsartan, perindopril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li><li>potassium phosphates, iv<p>valsartan and potassium phosphates, iv both increase  serum potassium. Avoid or Use Alternate Drug.</p></li><li>quinapril<p>valsartan, quinapril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li><li>ramipril<p>valsartan, ramipril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li><li>trandolapril<p>valsartan, trandolapril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li>